| Přispěvatelé: |
[Raigon Ponferrada,A, Guerrero Orriach,JL] Institute of Biomedical Research in Malaga [IBIMA], Malaga, Spain. [Raigon Ponferrada,A, Guerrero Orriach,JL, Malo Manso,A, Sepúlveda Haro,E, Romero Molina,S, Fontaneda Heredia,A, Baena Lopez,M, Cruz Mañas,J] Department of Anaesthesiology, Virgen de la Victoria University Hospital, Malaga, Spain.[Guerrero Orriach,JL] Department of Pharmacology and Pediatrics, School of Medicine, University of Malaga, Malaga, Spain. [Guerrero Orriach,JL] Member of COST Action 15204. |
| Popis: |
Cancer remains a primary cause of morbidity and mortality worldwide, and its incidence continues to increase. The most common cause of death in cancer patients is tumour recurrence. Surgery is the gold standard in the treatment of most tumours. However, cancer surgery can lead to the release of tumour cells into the systemic circulation. Surgical stress and several perioperative factors have been suggested to boost tumour growth, thereby increasing the risk of metastatic recurrence. Preclinical and clinical studies suggest that anaesthetics and adjuvants administered during the perioperative period may impact cancer recurrence and survival. This document summarises the current evidence regarding the effects of anaesthetic drugs and analgesic techniques on the immune system, systemic inflammatory response and tumour cells, as well as their impact on cancer recurrence. Yes |
